• Je něco špatně v tomto záznamu ?

BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment

Y. Huang, S. Qu, G. Zhu, F. Wang, R. Liu, X. Shen, D. Viola, R. Elisei, E. Puxeddu, L. Fugazzola, C. Colombo, B. Jarzab, A. Czarniecka, AK. Lam, C. Mian, F. Vianello, L. Yip, G. Riesco-Eizaguirre, P. Santisteban, CJ. O'Neill, MS. Sywak, R....

. 2018 ; 110 (4) : 362-370.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19013005

Grantová podpora
NV16-32665A MZ0 CEP - Centrální evidence projektů

Background: Precise risk stratification-based treatment of solitary intrathyroidal papillary thyroid cancer (SI-PTC) that is larger than 1.0 cm and 4.0 cm or less is undefined. Methods: A genetic-clinical risk study was performed on BRAF V600E in 955 patients (768 women and 187 men) with SI-PTC, with median age of 46 years and median clinical follow-up time of 64 months at 11 medical centers in six countries. The chi-square test or, for analyses with small numbers, Fisher's exact test was performed to compare recurrence rates. Recurrence-free probability was estimated by Kaplan-Meier (KM) analysis, and the independent effect of BRAF mutation on the recurrence was analyzed by Cox regression and Cox proportional hazard analyses. All statistical tests were two-sided. Results: Recurrence of SI-PTC larger than 1.0 cm and 4.0 cm or less was 9.5% (21/221) vs 3.4% (11/319) in BRAF mutation vs wild-type BRAF patients, with a hazard ratio (HR) of 3.03 (95% confidence interval [CI] = 1.46 to 6.30) and a patient age- and sex-adjusted hazard ratio of 3.10 (95% CI = 1.49 to 6.45, P = .002). Recurrence rates of SI-PTC larger than 2.0 cm and 4.0 cm or less were 16.5% (13/79) vs 3.6% (5/139) in mutation vs wild-type patients (HR = 5.44, 95% CI = 1.93 to 15.34; and adjusted HR = 5.58, 95% CI = 1.96 to 15.85, P = .001). Recurrence rates of SI-PTC larger than 3.0 cm and 4 cm or less were 30.0% (6/20) vs 1.9% (1/54) in mutation vs wild-type patients (HR = 18.40, 95% CI = 2.21 to 152.98; and adjusted HR = 14.73, 95% CI = 1.74 to 124.80, P = .01). Recurrences of mutation-positive SI-PTC were comparable with those of counterpart invasive solitary PTC, around 20% to 30%, in tumors larger than 2.0 cm to 3.0 cm. BRAF mutation was associated with a statistically significant decrease in recurrence-free patient survival on KM analysis, particularly in SI-PTC larger than 2.0 cm and 4.0 cm or less. Similar results were obtained in conventional SI-PTC. The negative predictive values of BRAF mutation for recurrence were 97.8% (95% CI = 96.3% to 98.8%) for general SI-PTC and 98.2% (95% CI = 96.3% to 99.3%) for conventional SI-PTC. Conclusions: BRAF V600E identifies a subgroup of SI-PTC larger than 1.0 cm and 4.0 cm or less, particularly tumors larger than 2.0 cm and 4.0 cm or less, that has high risk for recurrence comparable with that of invasive solitary PTC, making more aggressive treatment reasonable.

Biomedical Research Institute Alberto Sols Consejo Superior de Investigaciones Cientificas and Universidad Autonoma de Madrid 28029 Madrid Spain Ciberonc Health Institute Carlos 3 28029 Madrid Spain

Cancer Molecular Pathology of School of Medicine and Menzies Health Institute Queensland Griffith University Gold Coast Australia

Department of Endocrinology and Metabolism and the Shanghai Research Center of Thyroid Diseases The Shanghai Tenth People's Hospital Tongji University School of Medicine Shanghai China

Department of Endocrinology and Nutrition Hospital Universitario La Paz and Hospital Universitario de Mostoles 28029 Madrid Spain Biomedical Research Institute Alberto Sols Consejo Superior de Investigaciones Cientificas and Universidad Autonoma de Madrid 28029 Madrid Spain Ciberonc Health Institute Carlos 3 28029 Madrid Spain

Department of Internal Medicine University of Perugia Perugia Italy

Department of Medicine Endocrinology Unit University of Padua Padua Italy

Department of Molecular Endocrinology Institute of Endocrinology Prague Czech Republic

Division of Endocrine and Metabolic Diseases IRCCS Istituto Auxologico Italiano and Department of Pathophysiology and Transplantation University of Milan Milan Italy

Endocrine Surgical Unit The University of Sydney Sydney Australia

Endocrine Unit Department of Clinical and Experimental Medicine University of Pisa Pisa Italy

Laboratory for Cellular and Molecular Thyroid Research Division of Endocrinology Diabetes and Metabolism Department of Medicine Johns Hopkins University School of Medicine Baltimore MD

Laboratory for Cellular and Molecular Thyroid Research Division of Endocrinology Diabetes and Metabolism Department of Medicine Johns Hopkins University School of Medicine Baltimore MD Department of Endocrinology and Metabolism and the Shanghai Research Center of Thyroid Diseases The Shanghai Tenth People's Hospital Tongji University School of Medicine Shanghai China

Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology Gliwice Poland

University of Pittsburgh School of Medicine Pittsburgh PA

Veneto Institute of Oncology IRCCS Padua Italy

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19013005
003      
CZ-PrNML
005      
20190412111103.0
007      
ta
008      
190405s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1093/jnci/djx227 $2 doi
035    __
$a (PubMed)29165667
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Huang, Yueye $u Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. Department of Endocrinology and Metabolism and the Shanghai Research Center of Thyroid Diseases, The Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
245    10
$a BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment / $c Y. Huang, S. Qu, G. Zhu, F. Wang, R. Liu, X. Shen, D. Viola, R. Elisei, E. Puxeddu, L. Fugazzola, C. Colombo, B. Jarzab, A. Czarniecka, AK. Lam, C. Mian, F. Vianello, L. Yip, G. Riesco-Eizaguirre, P. Santisteban, CJ. O'Neill, MS. Sywak, R. Clifton-Bligh, B. Bendlova, V. Sýkorová, M. Xing,
520    9_
$a Background: Precise risk stratification-based treatment of solitary intrathyroidal papillary thyroid cancer (SI-PTC) that is larger than 1.0 cm and 4.0 cm or less is undefined. Methods: A genetic-clinical risk study was performed on BRAF V600E in 955 patients (768 women and 187 men) with SI-PTC, with median age of 46 years and median clinical follow-up time of 64 months at 11 medical centers in six countries. The chi-square test or, for analyses with small numbers, Fisher's exact test was performed to compare recurrence rates. Recurrence-free probability was estimated by Kaplan-Meier (KM) analysis, and the independent effect of BRAF mutation on the recurrence was analyzed by Cox regression and Cox proportional hazard analyses. All statistical tests were two-sided. Results: Recurrence of SI-PTC larger than 1.0 cm and 4.0 cm or less was 9.5% (21/221) vs 3.4% (11/319) in BRAF mutation vs wild-type BRAF patients, with a hazard ratio (HR) of 3.03 (95% confidence interval [CI] = 1.46 to 6.30) and a patient age- and sex-adjusted hazard ratio of 3.10 (95% CI = 1.49 to 6.45, P = .002). Recurrence rates of SI-PTC larger than 2.0 cm and 4.0 cm or less were 16.5% (13/79) vs 3.6% (5/139) in mutation vs wild-type patients (HR = 5.44, 95% CI = 1.93 to 15.34; and adjusted HR = 5.58, 95% CI = 1.96 to 15.85, P = .001). Recurrence rates of SI-PTC larger than 3.0 cm and 4 cm or less were 30.0% (6/20) vs 1.9% (1/54) in mutation vs wild-type patients (HR = 18.40, 95% CI = 2.21 to 152.98; and adjusted HR = 14.73, 95% CI = 1.74 to 124.80, P = .01). Recurrences of mutation-positive SI-PTC were comparable with those of counterpart invasive solitary PTC, around 20% to 30%, in tumors larger than 2.0 cm to 3.0 cm. BRAF mutation was associated with a statistically significant decrease in recurrence-free patient survival on KM analysis, particularly in SI-PTC larger than 2.0 cm and 4.0 cm or less. Similar results were obtained in conventional SI-PTC. The negative predictive values of BRAF mutation for recurrence were 97.8% (95% CI = 96.3% to 98.8%) for general SI-PTC and 98.2% (95% CI = 96.3% to 99.3%) for conventional SI-PTC. Conclusions: BRAF V600E identifies a subgroup of SI-PTC larger than 1.0 cm and 4.0 cm or less, particularly tumors larger than 2.0 cm and 4.0 cm or less, that has high risk for recurrence comparable with that of invasive solitary PTC, making more aggressive treatment reasonable.
650    _2
$a dospělí $7 D000328
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a papilární karcinom $x genetika $x patologie $7 D002291
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a mutace $7 D009154
650    _2
$a lokální recidiva nádoru $x genetika $x patologie $7 D009364
650    12
$a individualizovaná medicína $7 D057285
650    _2
$a prognóza $7 D011379
650    _2
$a protoonkogenní proteiny B-raf $x genetika $7 D048493
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a míra přežití $7 D015996
650    _2
$a nádory štítné žlázy $x genetika $x patologie $7 D013964
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Qu, Shen $u Department of Endocrinology and Metabolism and the Shanghai Research Center of Thyroid Diseases, The Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
700    1_
$a Zhu, Guangwu $u Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
700    1_
$a Wang, Fei $u Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
700    1_
$a Liu, Rengyun $u Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
700    1_
$a Shen, Xiaopei $u Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
700    1_
$a Viola, David $u Endocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
700    1_
$a Elisei, Rossella $u Endocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
700    1_
$a Puxeddu, Efisio $u Department of Internal Medicine, University of Perugia, Perugia, Italy.
700    1_
$a Fugazzola, Laura $u Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, and Department of Pathophysiology and Transplantation, University of Milan, Milan Italy.
700    1_
$a Colombo, Carla $u Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, and Department of Pathophysiology and Transplantation, University of Milan, Milan Italy.
700    1_
$a Jarzab, Barbara $u Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland.
700    1_
$a Czarniecka, Agnieszka $u Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland.
700    1_
$a Lam, Alfred K $u Cancer Molecular Pathology of School of Medicine and Menzies Health Institute Queensland, Griffith University, Gold Coast, Australia.
700    1_
$a Mian, Caterina $u Department of Medicine, Endocrinology Unit, University of Padua, Padua, Italy.
700    1_
$a Vianello, Federica $u Veneto Institute of Oncology, IRCCS, Padua, Italy.
700    1_
$a Yip, Linwah $u University of Pittsburgh School of Medicine, Pittsburgh, PA.
700    1_
$a Riesco-Eizaguirre, Garcilaso $u Department of Endocrinology and Nutrition Hospital Universitario La Paz and Hospital, Universitario de Mostoles, 28029 Madrid, Spain. Biomedical Research Institute "Alberto Sols," Consejo Superior de Investigaciones Cientificas and Universidad Autonoma de Madrid, 28029 Madrid, Spain. Ciberonc, Health Institute Carlos III, 28029 Madrid, Spain.
700    1_
$a Santisteban, Pilar $u Biomedical Research Institute "Alberto Sols," Consejo Superior de Investigaciones Cientificas and Universidad Autonoma de Madrid, 28029 Madrid, Spain. Ciberonc, Health Institute Carlos III, 28029 Madrid, Spain.
700    1_
$a O'Neill, Christine J $u Endocrine Surgical Unit, The University of Sydney, Sydney, Australia.
700    1_
$a Sywak, Mark S $u Endocrine Surgical Unit, The University of Sydney, Sydney, Australia.
700    1_
$a Clifton-Bligh, Roderick $u Endocrine Surgical Unit, The University of Sydney, Sydney, Australia.
700    1_
$a Bendlova, Bela $u Department of Molecular Endocrinology Institute of Endocrinology, Prague, Czech Republic.
700    1_
$a Sýkorová, Vlasta $u Department of Molecular Endocrinology Institute of Endocrinology, Prague, Czech Republic.
700    1_
$a Xing, Mingzhao $u Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
773    0_
$w MED00003002 $t Journal of the National Cancer Institute $x 1460-2105 $g Roč. 110, č. 4 (2018), s. 362-370
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29165667 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20190412111122 $b ABA008
999    __
$a ok $b bmc $g 1392315 $s 1051310
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 110 $c 4 $d 362-370 $i 1460-2105 $m Journal of the National Cancer Institute $n J Natl Cancer Inst $x MED00003002
GRA    __
$a NV16-32665A $p MZ0
LZP    __
$a Pubmed-20190405

Najít záznam

Citační ukazatele

Možnosti archivace